The law defines it as a facility at one location that compounds sterile drugs, has registered as an outsourcing facility and meets all the requirements of section 503B. Unlike an ordinary compounding pharmacy, it must follow current good manufacturing practice, the quality rules that apply to drug factories, and it may supply hospitals and clinics without a prescription for a named patient. Its products are still not FDA-approved.1,2
Where it came from
Section 503B was created by the Drug Quality and Security Act, signed into law on November 27, 2013. Congress passed it after the 2012 fungal meningitis outbreak, in which contaminated drugs from a Massachusetts compounding pharmacy caused more than 750 infections and more than 60 deaths in 20 states.2 The new category was voluntary: compounders could choose to register and accept stricter rules in exchange for the right to make drugs without a prescription for each patient.
Office stock
The practical difference from a 503A pharmacy is who can order. A 503A pharmacy compounds on a valid prescription for an identified patient. An outsourcing facility may also fill an order from a health care provider, such as a hospital, that is not for any one patient, which FDA calls office stock.2 That is the route by which compounded drugs can reach a clinic's shelves without a prescription for each patient, and it is open only to registered outsourcing facilities.
The rules it follows
- Quality. It must comply with current good manufacturing practice. It is exempt from FDA approval and from labeling with adequate directions for use, but not from those quality rules.
- Inspections. FDA inspects outsourcing facilities on a risk-based schedule.
- Adverse events. It must report them to FDA. State-licensed pharmacies that are not outsourcing facilities do not have to, which is one reason FDA calls its count of reports on compounded GLP-1s too low: 990 for semaglutide and more than 730 for tirzepatide by May 31, 2026.3
- Product reports. It must give FDA a list of the drugs it compounded in the previous 6 months when it registers, and again every June and December. FDA keeps the last two years of those reports in a searchable database.
- Fees. FDA charges outsourcing facility fees.
FDA, information for outsourcing facilities.1
What it may make from bulk ingredients
An outsourcing facility may compound from a bulk drug substance, the raw active ingredient, only in two cases. The first is to make a drug that is on FDA's drug shortage list at the time of compounding, distribution and dispensing. The second is when the substance is on FDA's 503B bulks list of substances with a clinical need.4 FDA develops that list on an ongoing basis as it evaluates nominated substances, with advice from its Pharmacy Compounding Advisory Committee.2,4
What it means for GLP-1 medicines
While semaglutide and tirzepatide were on the shortage list, outsourcing facilities could make them from bulk. The tirzepatide shortage was declared resolved on December 19, 2024, and the grace period for outsourcing facilities ended on March 19, 2025; the semaglutide shortage ended on February 21, 2025.5 Today an outsourcing facility may not use bulk semaglutide, because it is on neither list. On April 30, 2026 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, saying it found no clinical need for outsourcing facilities to compound them from bulk.6
How to check a facility
FDA publishes a list of registered outsourcing facilities and the product report database described above.1 A product that claims to come from an outsourcing facility can be checked against both. Our page on compounded semaglutide lists the other warning signs FDA has described for GLP-1 products sold online.
Sources
- U.S. Food and Drug Administration. Information for outsourcing facilities. Content current as of March 29, 2022, read November 20, 2026. fda.gov
- U.S. Food and Drug Administration. Compounding laws and policies. Content current as of December 17, 2024, read November 20, 2026. fda.gov
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov
- U.S. Food and Drug Administration. Bulk drug substances used in compounding. Content current as of March 26, 2026, read November 20, 2026. fda.gov
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Entries of December 19, 2024 to April 1, 2026. fda.gov
- U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Press announcement, April 30, 2026. fda.gov
Related analyses
Compounded semaglutide and tirzepatide in 2026: what FDA allows, what it has reported, and what to check
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Zepbound cost: what you pay with insurance, without it, and over a year
Wegovy cost: what the pen and the pill cost with insurance, without it, and over a year
Log which pharmacy filled each dose, so you know exactly what you took.
Open Dose Insider